20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids

Topical Corticosteroids (TCS): Cellular Mechanisms & Pharmacodynamics

Topical corticosteroids (TCS) remain the foundational pharmacotherapy for non-infectious inflammatory dermatoses across Europe. Their clinical utility derives from four interrelated biological properties: anti-inflammatory, immunosuppressive, antiproliferative, and vasoconstrictive actions.

Molecular Mechanism of Action

1. Receptor Binding & Translocation: Corticosteroids are lipophilic molecules that passively cross the plasma membrane of cutaneous cells (keratinocytes, fibroblasts, endothelial cells, and infiltrating leukocytes). Within the cytoplasm, they bind to the specific glucocorticoid receptor (GR), which is stabilized in an inactive monomeric state by molecular chaperones, including heat shock protein 90 (Hsp90) and Hsp70. Ligand binding induces a conformational dissociation of Hsp90, allowing ligand-bound GR monomers to homodimerize and undergo rapid nuclear translocation via importin proteins.
2. Transrepression (Anti-Inflammatory Axis): In the nucleus, monomeric and dimeric GR complexes physically interact with and cross-repress major pro-inflammatory transcription factors, predominantly nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). This transrepression downregulates the transcription of pivotal inflammatory cytokines (including IL-1α, IL-1β, IL-2, IL-6, IL-8, and TNF-α), chemokines, cell adhesion molecules (ICAM-1, VCAM-1, E-selectin), and inducible enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).
3. Transactivation (Anti-Inflammatory Protein Synthesis): Homodimeric GR complexes bind directly to specific palindromic DNA sequences termed glucocorticoid response elements (GRE) in the promoter regions of target genes. This triggers the transcription of anti-inflammatory proteins, most notably annexin A1 (lipocortin-1). Annexin A1 directly inhibits cytosolic phospholipase A2 (cPLA2), shutting down the release of arachidonic acid from cell membrane phospholipids and consequently halting downstream synthesis of inflammatory prostaglandins and leukotrienes.
4. Vasoconstriction: Corticosteroids induce local capillary and arteriolar vasoconstriction in the superficial dermal microvasculature. This is mediated through the potentiation of alpha-adrenergic vasoconstrictive responses and the suppression of vasodilatory mediators (including nitric oxide and prostacyclin). The degree of cutaneous blanching correlates directly with clinical anti-inflammatory potency and serves as the pharmacodynamic foundation of the Stoughton-McKenzie human vasoconstrictor assay, the regulatory standard used to classify topical steroid potency.

---

Potency Classification Systems: European 4-Class vs. United States 7-Class

Understanding the divergence between international classification systems is critical for interpreting guidelines and clinical literature.

The European 4-Class System

Europe utilizes a straightforward four-tier classification system established by the British National Formulary (BNF) and standardized across European dermatology:

• Class I: Mild (lowest potency)
• Class II: Moderate
• Class III: Potent
• Class IV: Very Potent / Superpotent (highest potency)

The United States 7-Class System

The United States system divides topical steroids into seven potency groups, where the numbering runs in the exact opposite direction:

• Class 1: Superpotent (equivalent to European Class IV)
• Class 2: Potent
• Class 3: Upper Mid-Strength
• Class 4: Mid-Strength
• Class 5: Lower Mid-Strength
• Class 6: Mild
• Class 7: Least Potent (equivalent to European Class I)

Classification Warning: Always check whether a text or case refers to the European or US classification. In Europe, Class I is the WEAKEST and Class IV is the STRONGEST. In the US system, Class 1 is the STRONGEST and Class 7 is the WEAKEST.

Comprehensive European TCS Potency Classification Table

---

Vehicle Pharmacology & Anatomical Penetration Dynamics

The vehicle (base) in which the active corticosteroid molecule is incorporated is a decisive pharmacological determinant of cutaneous bioavailability, clinical efficacy, and patient adherence.

Vehicle Characteristics and Clinical Indications

1. Ointments (Lipophilic Base):
   • Composed primarily of hydrocarbons (petrolatum/paraffin) with little to no water.
   • Pharmacological Action: Highly occlusive, traps transepidermal water, maximally hydrates the stratum corneum, and facilitates the highest drug penetration of any vehicle. Can convert a mid-potency molecule into a high-potency clinical response.
   • Indications: Chronic, dry, scaly, lichenified, or hyperkeratotic plaques (e.g., chronic plaque psoriasis, lichen simplex chronicus).
   • Contraindications & Traps: Acute weeping/exudative dermatoses (prevents evaporative heat loss, worsening exudation), acute intertriginous flexures (causes severe maceration), hairy anatomical regions (causes occlusive folliculitis).
2. Creams (Emulsion Base):
   • Oil-in-water emulsions (semi-solid, containing water, oils, and emulsifying agents).
   • Pharmacological Action: Absorbs quickly, leaves minimal residue, and provides a soothing, cooling effect via water evaporation.
   • Indications: Subacute or acute dermatoses, exudative lesions, flexural/intertriginous skin folds, daytime application where cosmetic elegance is required.
   • Disadvantage: Contains preservatives (parabens, phenoxyethanol) and emulsifiers that carry a significantly higher incidence of allergic contact dermatitis compared to ointments.
3. Lotions, Solutions, Gels & Foams:
   • Lotions and Solutions: Water-, alcohol-, or propylene glycol-based liquid preparations. Ideal for hairy areas (scalp, chest, beard) and broad surface areas without clumping hair.
   • Gels: Semi-solid systems that liquefy upon skin contact and dry rapidly to form a thin film. Excellent for the scalp, face, and oral mucosa; can cause stinging on fissured or denuded skin due to alcohol content.
   • Foams: Pressurized aerosolized formulations that break down quickly upon cutaneous contact. High bioavailability, excellent spreadability, rapid drying, and highest patient satisfaction ratings for scalp and extensive plaque psoriasis.

Anatomical Gradients of Percutaneous Absorption

Percutaneous absorption varies by several orders of magnitude across anatomical sites depending on stratum corneum thickness, hair follicle density, and local skin hydration:

• Plantar arch / Sole of foot: 0.14× baseline (thick stratum corneum; minimal penetration)
• Palm of hand: 0.8× baseline
• Volar forearm: 1.0× (standard pharmacological reference baseline)
• Scalp: 3.5× to 4.0× baseline
• Forehead: 6.0× baseline
• Cheek / Face: 13.0× baseline
• Eyelids: 30.0× to 40.0× baseline
• Scrotum / Vulva: 36.0× to 42.0× baseline (ultra-thin barrier, high vascularity; extreme risk of systemic absorption and rapid atrophy)

---

Quantitative Dosing: The Fingertip Unit (FTU) System

To prevent under-treatment (resulting in chronic disease failure) and over-application (driving local atrophy and systemic suppression), dermatologists rely on the standardized Fingertip Unit (FTU) metric, introduced by Long and Finlay in 1991.

Definition and Surface Coverage Metrics

• 1 FTU is defined as the amount of ointment or cream expressed from a tube with a standard 5 mm diameter nozzle, measured from the distal interphalangeal crease to the fleshy tip of an adult index finger.
• Weight Metric: 1 FTU weighs approximately 0.49 to 0.50 grams in an adult hand.
• The Rule of Hand: 1 FTU is sufficient to cover a skin surface area equal to two adult palm prints with the fingers closed (representing approximately 2% of an adult's total body surface area [BSA]).
• Consequently, 1 adult hand print = 0.5 FTU = 0.25 grams of topical medication.

Anatomical FTU & Gram Reference Guide for Adults

Prescription Calculation Pearl: For an adult patient with severe eczema requiring twice-daily whole-body application, the physician must prescribe approximately 40 g per day, which equates to about 280 g per week. Under-prescribing small 30 g tubes for extensive disease is a common clinical error that leads to treatment failure.

---

Adverse Effect Profiles: Cutaneous and Systemic Toxicities

Cutaneous (Local) Adverse Effects

1. Epidermal Thinning & Dermal Atrophy: The hallmark adverse effect of prolonged or inappropriately potent TCS use. Corticosteroids inhibit basal keratinocyte mitotic division (epidermal atrophy) and profoundly downregulate fibroblast proliferation and procollagen type I and type III gene transcription. Loss of ground substance (glycosaminoglycans) and dermal structural scaffolding leads to paper-thin, fragile, translucent skin with visible underlying subcutaneous venules.
2. Telangiectasia: Arises from loss of perivascular connective tissue support combined with chronic endothelial dilatation.
3. Striae Distensae: Dermal elastolysis and mechanical rupture of collagen bundles along cutaneous lines of cleavage. Striae are permanent and irreversible; they begin as erythematous or violaceous bands (striae rubrae) before progressing to permanent, atrophic, white scars (striae albae). Highest risk in intertriginous flexures (groin, axillae) where occlusion naturally amplifies steroid potency.
4. Purpura & Senile-like Ecchymoses: Microvascular fragility and extravasation of red blood cells into the atrophic dermis following minimal shear trauma.
5. Steroid Rosacea & Perioral Dermatitis: Occurs when potent TCS are applied to the central face. Characterized by follicular erythema, pinpoint inflammatory papules, pustules, and telangiectasias around the mouth and nasolabial folds, exacerbated by secondary overgrowth of Demodex folliculorum mites.
6. Tachyphylaxis: The progressive loss of clinical therapeutic efficacy during repetitive, continuous TCS administration. Pharmacologically driven by desensitization and downregulation of intracellular glucocorticoid receptors.
7. Rebound Flares: Severe, acute disease exacerbation following abrupt TCS cessation, particularly dangerous in psoriasis where sudden withdrawal of potent steroids can trigger life-threatening generalized pustular psoriasis (von Zumbusch) or erythroderma.
8. Tinea Incognito: A fungal dermatophyte infection whose typical clinical morphology (raised, erythematous, scaling annular border) has been modified and masked by topical steroid immunosuppression, leading to widespread erythematous plaques and extensive hyphal proliferation.
9. Allergic Contact Dermatitis: Can be triggered by the corticosteroid molecule itself (screened via patch testing with marker molecules: tixocortol pivalate, budesonide, hydrocortisone-17-butyrate) or vehicle excipients (propylene glycol, parabens, lanolin).

Systemic Adverse Effects

1. Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: Systemically absorbed corticosteroids suppress hypothalamic corticotropin-releasing hormone (CRH) and pituitary adrenocorticotropic hormone (ACTH) secretion through negative feedback. Risk factors include: Class III/IV potency, application over >10%–20% BSA, broken epidermal barriers (erythroderma, severe eczema), occlusion (plastic wrap, diapers), and pediatric age (higher BSA-to-body-weight ratio). Diagnosis is confirmed by a low early morning serum cortisol (<138 nmol/L) or a blunted response on a short synacthen (cosyntropin) stimulation test.
2. Iatrogenic Cushing Syndrome: Truncal obesity, moon facies, buffalo hump, hirsutism, and secondary arterial hypertension from prolonged massive systemic absorption.
3. Growth Retardation in Children: Chronic suppression of growth hormone pulsatility and epiphyseal chondrocyte proliferation.
4. Ophthalmic Complications: Application of potent steroids to periocular or eyelid skin can cause trans-scleral penetration, leading to open-angle glaucoma (increased outflow resistance in the trabecular meshwork) and posterior subcapsular cataracts.

---

Topical Calcineurin Inhibitors (TCIs): Tacrolimus & Pimecrolimus

Topical calcineurin inhibitors (TCIs) represent non-steroidal immunomodulatory macrolactams derived from Streptomyces species that offer targeted T-cell suppression without structural tissue degradation.

Pharmacological Mechanism of Action

1. Immunophilin Binding: Tacrolimus (FK506) and pimecrolimus cross the cell membrane and bind specifically to the intracellular immunophilin FK506-binding protein 12 (FKBP-12).
2. Calcineurin Phosphatase Inhibition: The drug-FKBP-12 binary complex binds with high affinity to and competitively inhibits calcineurin, a calcium- and calmodulin-dependent serine/threonine protein phosphatase.
3. Blockade of NFAT Nuclear Translocation: Under physiological conditions, antigen stimulation triggers intracellular calcium influx, activating calcineurin to dephosphorylate the cytoplasmic nuclear factor of activated T cells (NFAT). Dephosphorylated NFAT translocates into the nucleus to initiate transcription of pro-inflammatory cytokines. By blocking calcineurin phosphatase activity, TCIs prevent NFAT dephosphorylation, thereby silencing gene transcription for IL-2 (essential for T-cell clonal expansion), IL-3, IL-4, IL-5, IFN-γ, and TNF-α.
4. Mast Cell & Basophil Modulation: In addition to T-cell inhibition, TCIs stabilize cutaneous mast cells and basophils, suppressing IgE-mediated degranulation and histamine release.

Formulations, Concentrations & Anatomical Niches

• Tacrolimus (Ointment): Available in 0.1% (licensed for adults aged ≥16 years with moderate-to-severe atopic dermatitis) and 0.03% (licensed for children aged ≥2 years and adults).
• Pimecrolimus (Cream 1%): Less lipophilic with lower skin permeation; licensed for mild-to-moderate atopic dermatitis in patients aged ≥2 years.
• The Non-Atrophying Advantage: TCIs do not inhibit fibroblast proliferation, do not suppress procollagen gene expression, and do not induce glycosaminoglycan loss. Consequently, TCIs carry zero risk of cutaneous atrophy, telangiectasia, striae, or ocular glaucoma/cataracts.
• First-Line Anatomical Indications: Eyelids, periorbital skin, face, neck, axillae, inframammary folds, groin, and genital dermatoses (e.g., inverse psoriasis, lichen sclerosus, vitiligo, facial atopic dermatitis).
• Proactive Maintenance Protocol: In chronic recurrent atopic dermatitis, applying tacrolimus ointment twice weekly (e.g., Wednesday and Sunday) to previously affected, newly cleared skin zones significantly reduces flare frequency, prolongs remission intervals, and minimizes long-term corticosteroid reliance.

Adverse Effect Profile & The Capsaicin Phenomenon

• Application-Site Burning & Stinging: Experienced by up to 40%–50% of patients during the initial days of therapy. Mechanistically, tacrolimus binds to and activates transient receptor potential vanilloid 1 (TRPV1) capsaicin receptors on cutaneous sensory C-nerve fibers, provoking a massive initial release of substance P and calcitonin gene-related peptide (CGRP). With continued application over 3 to 7 days, sensory nerve terminals become depleted of neuropeptides, tachyphylaxis occurs, and burning resolves completely.
• Clinical Mitigation Pearls: Counsel patients in advance that burning is temporary; apply to completely dry skin; store ointment in the refrigerator; or pre-treat the skin with a mild topical steroid for 48–72 hours prior to initiating TCIs.
• Safety Black Box Warning Context: Regulatory agencies issued a class black box warning regarding potential lymphoma and non-melanoma skin cancer risks. However, long-term paediatric registries such as APPLES (tacrolimus) and PEER (pimecrolimus) have not shown a causal increase in malignancy with TCI therapy. Concurrent ultraviolet phototherapy (PUVA/UVB) should still be avoided.

---

Topical Retinoids: First to Fourth Generation

Topical retinoids are structural and functional analogues of Vitamin A that orchestrate gene transcription via nuclear receptor signaling.

Retinoid Classification & Molecular Selectivity

1. First-Generation (Non-aromatic):
   • Tretinoin (all-trans retinoic acid): Binds with broad affinity to all three retinoic acid receptor isoforms (RAR-α, RAR-β, RAR-γ). Photolabile (readily degraded by sunlight) and oxidized by benzoyl peroxide; must be applied exclusively at night and separated from benzoyl peroxide application unless formulated in specialized microencapsulated systems.
2. Third-Generation (Poly-aromatic):
   • Adapalene (Naphthoic acid derivative): Selectively targets RAR-β and RAR-γ. Highly lipophilic, penetrating deeply into pilosebaceous units. Chemically photostable and resistant to oxidation by benzoyl peroxide, enabling co-formulated fixed combinations.
   • Tazarotene (Acetylenic prodrug): Rapidly converted by cutaneous esterases into active tazarotenic acid, which selectively binds RAR-β and RAR-γ. Highly potent antiproliferative agent used in plaque psoriasis and acne.
3. Fourth-Generation (Selective):
   • Trifarotene: Specifically targets RAR-γ (>65-fold selectivity over RAR-α and RAR-β), the predominant RAR isoform expressed in the epidermis (>90% of cutaneous RAR). Exhibits potent comedolytic and anti-inflammatory activity at ultra-low systemic concentrations; licensed for facial and extensive truncal acne.

Intracellular Mechanism & Genomic Effects

Topical retinoids bind to nuclear Retinoic Acid Receptors (RAR), which form heterodimers with Retinoid X Receptors (RXR). The resulting RAR-RXR heterodimer binds to specific DNA sequences termed Retinoic Acid Response Elements (RARE) located in the promoter regions of target genes:

• Normalization of Follicular Keratinization: Accelerates corneocyte turnover and downregulates transglutaminase activity, loosening desmosomal intercellular adhesion in the follicular infundibulum. This expels existing mature plugs and prevents the formation of microcomedones (the obligate precursor of all inflammatory and non-inflammatory acne lesions).
• Anti-Inflammatory Modulation: Downregulates Toll-like receptor 2 (TLR-2) expression on keratinocytes and perifollicular macrophages, suppressing the inflammatory cascade triggered by Cutibacterium acnes.
• Extracellular Matrix Remodeling: Inhibits AP-1-mediated activation of matrix metalloproteinases (MMP-1, MMP-8, MMP-13), preserving dermal collagen and stimulating type I procollagen synthesis in photoaged skin.

Clinical Management of Retinoid Dermatitis

• Retinoid Dermatitis Manifestations: Characterized by localized erythema, dryness, superficial scaling, peeling, and cutaneous stinging, peaking during the first 2 to 4 weeks of therapy.
• Stepwise Mitigation Strategy:
  • Initiate therapy slowly: prescribe on alternate nights or twice weekly for the first 2 weeks, titrating upward as cutaneous tolerance develops.
  • Enforce strict quantity limits: a single pea-sized aliquot is sufficient to treat the entire facial surface.
  • Apply exclusively to completely dry skin (wait 20 to 30 minutes following facial cleansing; moisture increases skin permeability, driving rapid drug surges and severe irritation).
  • The "Sandwich" Buffering Technique: Applying a ceramide-rich moisturizer immediately before and/or after retinoid application mitigates barrier disruption without compromising comedolytic efficacy.
  • Photosensitivity Precautions: Thinning of the stratum corneum reduces natural UV dispersion, increasing susceptibility to acute sunburn. Evening application paired with daily broad-spectrum SPF 30–50+ sunscreen is mandatory.